What's new — COPD¶
Generated 2026-11-01 from the publication dates of every paper cited in this condition's pages.
This page answers a different question from the curation log. The log says when we last edited a page; this says how recent the evidence on those pages is — so you can tell settled ground from a field that is actively moving, and jump straight to what has emerged lately.
How much of this condition's evidence is recent¶
| Published within | Cited papers |
|---|---|
| last week | 0 |
| last month | 2 |
| last 2 months | 13 |
| last 3 months | 15 |
| last 6 months | 19 |
| last year | 24 |
| older than a year | 292 |
Counts are cumulative: a paper from last week also counts inside "last month". Dates are PubMed publication or e-publication dates, so a paper may have appeared online before its journal issue.
Newest evidence first¶
The most recent cited papers, with the pages that use them.
| Published | Paper | Cited on |
|---|---|---|
| 2026-10-02 | CONQUEST-ADVANCE: Achieving proDuctiVe implementAtioN of CONQUEST Quality Standards in COPD Care — Pragmat Obs Res ([PMID 42928880](https://pubmed.ncbi.nlm.nih.gov/42928880/){target="_blank" rel="noopener"}) | guidelines |
| 2026-10-02 | Comparative Real-World Effectiveness of Dupilumab, Mepolizumab, and Benralizumab in Patients with Chronic Obstructive Pulmonary Disease: A Propensity Score-Matched Cohort Study — Drug Des Devel Ther ([PMID 42928777](https://pubmed.ncbi.nlm.nih.gov/42928777/){target="_blank" rel="noopener"}) | clinical-trials-landscape |
| 2026-10-01 | Needs among persons with advanced COPD and their informal caregivers: a multi-perspective qualitative study focusing on the potential role of palliative care — BMC Pulm Med ([PMID 42897575](https://pubmed.ncbi.nlm.nih.gov/42897575/){target="_blank" rel="noopener"}) | patient-experience-and-advocacy |
| 2026-09-09 | AARC Clinical Practice Guideline: Adult Patients Transitioning From the Hospital on Oxygen — Respir Care ([PMID 42713935](https://pubmed.ncbi.nlm.nih.gov/42713935/){target="_blank" rel="noopener"}) | oxygen-and-ventilatory-support |
| 2026-09-08 | Tozorakimab to Prevent COPD Exacerbations — N Engl J Med ([PMID 42708515](https://pubmed.ncbi.nlm.nih.gov/42708515/){target="_blank" rel="noopener"}) | clinical-trials-landscape, guidelines |
| 2026-09-06 | Metoprolol in Chronic Obstructive Pulmonary Disease without Cardiovascular Disease — NEJM Evid ([PMID 42701865](https://pubmed.ncbi.nlm.nih.gov/42701865/){target="_blank" rel="noopener"}) | comorbidity-and-systemic-effects, guidelines |
| 2026-09-03 | Extracorporeal CO(2) elimination for acute exacerbation of severe COPD requiring invasive mechanical ventilation: a randomized controlled trial (the X-COPD trial) — Crit Care ([PMID 42693471](https://pubmed.ncbi.nlm.nih.gov/42693471/){target="_blank" rel="noopener"}) | exacerbations-and-acute-care |
| 2026-09-02 | Metered-Dose Liquid Nitrogen Cryospray for Chronic Bronchitis: Results From the Prospective, Sham-Controlled Trial (SPRAY-CB) — Am J Respir Crit Care Med ([PMID 42768446](https://pubmed.ncbi.nlm.nih.gov/42768446/){target="_blank" rel="noopener"}) | emphysema-procedures-and-transplant |
| 2026-09-02 | Portable low-flow nasal oxygen versus ambient air in patients with chronic lung disease and exercise-induced hypoxaemia: a randomised controlled crossover non-inferiority trial — BMJ Open Respir Res ([PMID 42767802](https://pubmed.ncbi.nlm.nih.gov/42767802/){target="_blank" rel="noopener"}) | oxygen-and-ventilatory-support |
| 2026-09-01 | Mepolizumab efficacy in chronic obstructive pulmonary disease: insights from longitudinal patterns of blood eosinophil counts and their variability across 3 clinical trials — Am J Respir Crit Care Med ([PMID 42265988](https://pubmed.ncbi.nlm.nih.gov/42265988/){target="_blank" rel="noopener"}) | clinical-trials-landscape |
| 2026-09-01 | Establishing the top 10 research priorities for lung volume reduction treatment for people with COPD — Thorax ([PMID 42248680](https://pubmed.ncbi.nlm.nih.gov/42248680/){target="_blank" rel="noopener"}) | emphysema-procedures-and-transplant |
| 2026-09-01 | Dupilumab in chronic obstructive pulmonary disease: a pooled analysis of emergency department visits, hospital admissions, and systemic corticosteroid use — Am J Respir Crit Care Med ([PMID 42153327](https://pubmed.ncbi.nlm.nih.gov/42153327/){target="_blank" rel="noopener"}) | clinical-trials-landscape |
| 2026-09-01 | Astegolimab for chronic obstructive pulmonary disease with frequent exacerbations: pooled analysis of the ALIENTO and ARNASA trials — Am J Respir Crit Care Med ([PMID 42148875](https://pubmed.ncbi.nlm.nih.gov/42148875/){target="_blank" rel="noopener"}) | clinical-trials-landscape |
| 2026-08-06 | The use of spirometry to define airflow obstruction and diagnose COPD — Eur Respir J ([PMID 42562597](https://pubmed.ncbi.nlm.nih.gov/42562597/){target="_blank" rel="noopener"}) | diagnosis-spirometry-and-case-finding, guidelines |
| 2026-08-02 | Alpha 1 antitrypsin augmentation therapy for alpha 1 antitrypsin deficiency-associated lung disease — Cochrane Database Syst Rev ([PMID 42626936](https://pubmed.ncbi.nlm.nih.gov/42626936/){target="_blank" rel="noopener"}) | genetics-and-alpha-1-antitrypsin |
| 2026-07-02 | Peri-procedural vs. post-procedural mortality after endobronchial valve treatment for severe emphysema: a systematic review and meta-analysis of randomized controlled trials — Expert Rev Med Devices ([PMID 42500855](https://pubmed.ncbi.nlm.nih.gov/42500855/){target="_blank" rel="noopener"}) | emphysema-procedures-and-transplant |
| 2026-07-01 | The JRS guideline for the management of chronic obstructive pulmonary disease 7th edition 2026 — Respir Investig ([PMID 42447589](https://pubmed.ncbi.nlm.nih.gov/42447589/){target="_blank" rel="noopener"}) | guidelines |
| 2026-06-01 | Coexistence of COPD or asthma in patients with bronchiectasis: a systematic review and meta-analysis — BMC Pulm Med ([PMID 42321713](https://pubmed.ncbi.nlm.nih.gov/42321713/){target="_blank" rel="noopener"}) | comorbidity-and-systemic-effects |
| 2026-05-05 | Associations of Mucus Plug With Prognosis in COPD: A Systematic Review and Meta-Analysis — Chest ([PMID 42097456](https://pubmed.ncbi.nlm.nih.gov/42097456/){target="_blank" rel="noopener"}) | biomarkers-and-imaging-phenotypes |
| 2026-05-01 | Safety and efficacy of astegolimab for COPD with frequent exacerbations regardless of baseline blood eosinophil counts (ALIENTO and ARNASA): randomised, double-blind, placebo-controlled, phase 2b and 3 trials — Lancet ([PMID 42150581](https://pubmed.ncbi.nlm.nih.gov/42150581/){target="_blank" rel="noopener"}) | clinical-trials-landscape |
| 2026-04-01 | Joint statement from GOLD/GLI regarding the use of spirometry to define airflow obstruction and diagnose COPD — Eur Respir J ([PMID 41748283](https://pubmed.ncbi.nlm.nih.gov/41748283/){target="_blank" rel="noopener"}) | diagnosis-spirometry-and-case-finding, guidelines |
| 2026-02-02 | Underrepresentation of Women in COPD Pharmacologic Trials Relative to Disease Burden: A Systematic Review and Meta-Analysis — Int J Chron Obstruct Pulmon Dis ([PMID 41773232](https://pubmed.ncbi.nlm.nih.gov/41773232/){target="_blank" rel="noopener"}) | clinical-trials-landscape |
| 2025-12-01 | Randomized Sham-controlled Trial of Targeted Lung Denervation in Patients with Chronic Obstructive Pulmonary Disease (AIRFLOW-3) — Am J Respir Crit Care Med ([PMID 40920914](https://pubmed.ncbi.nlm.nih.gov/40920914/){target="_blank" rel="noopener"}) | emphysema-procedures-and-transplant |
| 2025-11-04 | Reassessing the link between e-cigarette use and COPD: addressing critical methodological and conceptual flaws — NPJ Prim Care Respir Med ([PMID 41188266](https://pubmed.ncbi.nlm.nih.gov/41188266/){target="_blank" rel="noopener"}) | smoking-pollution-and-occupational-risk |
Trials — what has moved¶
48 registered trials are cited by this condition's pages. Registry records were re-checked live when this page was generated, so status, enrolment and results-posting below reflect ClinicalTrials.gov as of that date.
| Registry activity | Trials |
|---|---|
| trial records updated in the last week | 1 |
| trial records updated in the last month | 6 |
| trial records updated in the last 2 months | 9 |
| trial records updated in the last 3 months | 12 |
| trial records updated in the last 6 months | 12 |
| trial records updated in the last year | 16 |
Recently updated registrations¶
Posted efficacy and safety results¶
Trials whose sponsors have posted results to the registry. Adverse-event figures are participant counts summed across all arms as reported — read them against enrolment, and follow the registry link for the arm-by-arm breakdown that determines whether a signal is real.
| Results posted | Trial | Phase | N | Primary outcome | Serious AE | Other AE | Deaths |
|---|---|---|---|---|---|---|---|
| 2026-10-28 | A Study to Evaluate Astegolimab in Participants With Chronic Obstructi | PHASE3 | 1380 | Annualized Rate of Moderate and Severe COPD Exacerbations Over the 52- | 344 | 785 | 44 |
| 2026-10-16 | A Study to Evaluate the Efficacy and Safety of Astegolimab in Particip | PHASE2 | 1334 | Annualized Rate of Moderate and Severe COPD Exacerbations Over the 52- | 374 | 838 | 40 |
| 2026-10-15 | Study to Assess the Efficacy, Safety, and Tolerability of SAR440340/RE | PHASE3 | 1127 | Annualized Rate of Adjudicated Moderate or Severe Acute Exacerbation o | 222 | 268 | 18 |
| 2026-10-09 | Study to Assess the Efficacy, Safety, and Tolerability of SAR440340/RE | PHASE3 | 1234 | Former Smoker Cohort: Annualized Rate of Adjudicated Moderate or Sever | 284 | 281 | 39 |
| 2025-08-15 | Mepolizumab as Add-on Treatment IN Participants With COPD Characterize | PHASE3 | 806 | Annualized Rate of Moderate or Severe Exacerbations | 216 | 377 | 22 |
| 2025-03-17 | Pivotal Study to Assess the Efficacy, Safety and Tolerability of Dupil | PHASE3 | 935 | Annualized Rate of Moderate or Severe Chronic Obstructive Pulmonary Di | 144 | 245 | 22 |
| 2025-02-18 | Tezepelumab COPD Exacerbation Study | PHASE2 | 337 | Rate of Moderate or Severe COPD Exacerbations in Participants With Mod | 114 | 134 | 9 |
| 2024-02-28 | Pivotal Study to Assess the Efficacy, Safety and Tolerability of Dupil | PHASE3 | 939 | Annualized Rate of Moderate or Severe Chronic Obstructive Pulmonary Di | 139 | 340 | 17 |
| 2023-11-13 | A Phase 3 Clinical Trial to Evaluate the Safety and Efficacy of Ensife | PHASE3 | 763 | Least Square (LS) Mean Change From Baseline in Average Forced Expirato | 67 | 181 | 9 |
| 2023-07-24 | A Phase 3 Trial to Evaluate the Safety and Efficacy of Ensifentrine in | PHASE3 | 790 | Least Square (LS) Mean Change From Baseline in Average Forced Expirato | 45 | 114 | 5 |
| 2019-06-26 | Efficacy and Safety of Benralizumab in Moderate to Very Severe Chronic | PHASE3 | 2255 | Annual COPD Exacerbation Rate Over 56 Weeks Treatment Comparison for P | 606 | 982 | 74 |
| 2019-06-13 | Benralizumab Efficacy in Moderate to Very Severe Chronic Obstructive P | PHASE3 | 1656 | Annual COPD Exacerbation Rate Over 56 Weeks Treatment Comparison for P | 504 | 893 | 39 |
| 2018-04-06 | Efficacy and Safety of Mepolizumab as an Add-on Treatment in Chronic O | PHASE3 | 674 | Rate of Moderate or Severe Exacerbations | 185 | 421 | 21 |
| 2018-04-06 | Study to Evaluate Efficacy and Safety of Mepolizumab for Frequently Ex | PHASE3 | 837 | Rate of Moderate or Severe Exacerbations in Participants in the High S | 246 | 506 | 33 |
| 2016-08-09 | Study to Evaluate the Effect of Fluticasone Furoate/Vilanterol on Surv | PHASE3 | 16568 | Number of Participants With Death (Both on and Off Treatment) Due to A | 3780 | 7391 | 0 |
11 of these trials are still recruiting or active — see the condition's clinical trials page for the full landscape.
Which pages rest on the newest evidence¶
🔥 marks a page citing three or more papers from the last year — the pages worth re-reading if you have been away.
| Page | Newest citation | In last year | Total citations |
|---|---|---|---|
| clinical-trials-landscape | 2026-10-02 | 7 | 26 |
| guidelines | 2026-10-02 | 6 | 36 |
| patient-experience-and-advocacy | 2026-10-01 | 1 | 26 |
| oxygen-and-ventilatory-support | 2026-09-09 | 2 | 23 |
| comorbidity-and-systemic-effects | 2026-09-06 | 2 | 28 |
| exacerbations-and-acute-care | 2026-09-03 | 1 | 22 |
| emphysema-procedures-and-transplant | 2026-09-02 | 4 | 26 |
| diagnosis-spirometry-and-case-finding | 2026-08-06 | 2 | 32 |
| genetics-and-alpha-1-antitrypsin | 2026-08-02 | 1 | 23 |
| biomarkers-and-imaging-phenotypes | 2026-05-05 | 1 | 26 |
| smoking-pollution-and-occupational-risk | 2025-11-04 | 1 | 26 |
| epidemiology-and-global-burden | 2025-07-02 | 0 | 27 |
| red-flags-and-safety-concerns | 2025-07-01 | 0 | 26 |
| inflammation-and-endotypes | 2025-05-01 | 0 | 29 |
| overview | 2025-05-01 | 0 | 44 |
| small-airway-disease-and-emphysema | 2024-12-05 | 0 | 23 |
| stable-inhaled-therapy | 2024-12-04 | 0 | 25 |
| pulmonary-rehabilitation-and-self-management | 2023-08-15 | 0 | 18 |
Recency is not quality: an old paper may be the definitive one, and a new paper may not replicate. Use this to find movement, not to rank evidence. See open questions for what remains unresolved, and the curation log for when these pages were last revised.